RxDoctor Payments Data

Armistead Williams, MD

Neurology · New York, NYNPI 1073580908

Payments from drug & device makers

$20,124in general payments, 2019–2025

Across 4 payments — averaging $5031.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$20K
  • Biogen$65
  • Genentech, Inc.$48

What the payments were for

  • Education$113100%

General payments by program year

20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb2$20,011
Biogen1$65
Genentech, Inc.1$48

How this compares

$20,124 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$8,356,722
Medicare patients
331
Services billed
184,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5047$725,095
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$228,601
RebifInterferon Beta-1a/Albumin14$170,614
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5024$165,315
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$122,893
AmpyraDalfampridine13$110,802
TecfideraDimethyl Fumarate12$106,310
CopaxoneGlatiramer Acetate13$90,999
Dalfampridine ErDalfampridine202$80,729
CambiaDiclofenac Potassium12$20,943
MyrbetriqMirabegron21$19,849
Mycophenolate Mofetil125$8,905
GemtesaVibegron14$6,430
Methenamine Hippurate34$3,668
Baclofen134$3,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$65$106,31012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →